+1 (502) 904-2126   One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA   Site Map
ISSN: 2574 -1241

Impact Factor : 0.548

  Submit Manuscript

Research ArticleOpen Access

Use of Extracellular Vesicles for Cell-Free Regenerative Medicine in Osteochondral and Bone-Related Therapies

Volume 3 - Issue 2

Forteza-Genestra, M.A.†1,2; Antich-Rosselló, M.†1,2; Monjo, M.*1,2; Ramis, J.M.*1,2

  • Author Information Open or Close
    • 1Group of Cell Therapy and Tissue Engineering, Research Institute on Health Sciences (IUNICS), University of Balearic Islands, Spain
    • 2Balearic Islands Health Research Institute (IdISBa), Spain
    • Both authors have equally contributed to this work.

    *Corresponding author: Marta Monjo and Joana Maria Ramis, Group of Cell Therapy and Tissue Engineering, Research Institute on Health Sciences (IUNICS), University of Balearic Islands, Palma, Balearic Islands Health Research Institute (IdISBa), Spain

Received: March 13, 2018;   Published: March 27, 2018

DOI: 10.26717/BJSTR.2018.03.000888

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF


The tissue engineering paradigm considers cells, signals and scaffolds as the major elements of tissue engineering approaches to repair and/or regenerate tissues [1]. Unexpectedly, a paradigm shift is taking place in this field by the only use of extracellular vesicles (EVs) to deliver the right signals to the damaged tissue. In recent years, EVs role in intercellular signalling has begun to emerge [2]. EVs range in size from 30 to 1000 nm and can be derived from the endosomal system (exosomes, 70-150 nm) or produced by outward budding of the plasma membrane (micro vesicles, 100-1000 nm) [3,4]. All EVs are enriched in proteins, lipids, and nucleic acids (DNA, mRNA, miRNA, tRNA) that can be delivered to recipient cells for cellto- cell communication [5]. In fact, EVs have recently evolved to be vital components of cell-based therapies based on the observations that the beneficial effects of cell therapies could not be attributed to cell survival and differentiation, leading to the thought that cell therapies act in a paracrine rather than in a cellular manner [6]. This shift was based on in vivo data showing that stem cell engraftment and differentiation at injury sites was very low and transient [7-11]. And on the observation that conditioned media from cultured stem cells reproduces some of the beneficial effects of intact cells [12,13]. This paracrine effect exerted by stem cells would depend on their capacity to secrete soluble factors [14], but also, by the release of EVs [15]. In particular, preclinical models studying graft versus host disease, acute kidney failure and ischemic stroke suggest that EVs exert the stem cells’ therapeutic effects [16-18].

Abbreviations: C28/I2: Human Primary Chondrocytes Cell Line; FLS: Fibroblast Like Synoviocyte; HASC: Human adipose stem cells; hBMMSC: Human Bone Marrow Mesenchymal Stem Cells; hESC: Human Embryonic Stem Cells; hiPS-MSC: Human-Induced Pluripotent Stem Cell- Derived Mesenchymal Stem Cells; hMSC: Primary Human Marrow Derived Stromal Cells; HUVEC: Human Umbilical Vein Endothelial Cells; mBM-MSC: Murine Bone Marrow Mesenchymal Stem Cells; MC3T3-E1: Murinepreosteoblastic Cell Line; RA: Rheumatoid Arthritis; SMSCS: Synovial Mesenchymal Stem Cells

Introduction| Acknowledgement| References|